Ramy

M.D- Hemato-Oncology fellow. USJ/HDF/Gustave Roussy Interne d’oncologie médicale- Thoracic oncology fellow CHUM/🇱🇧 🇨🇦/ Man United, travel, series, ☕️, 🍺

[Normand Blais, MD @NormandBlais]

Changement d’approche pour les cancers gastriques opérables. À venir bientôt au 🇨🇦.

[Daisuke Kotani, MD, Ph.D 小谷 大輔 @DaisukeKotani]

Key guideline differences in 1L ESCC
🇪🇺ESMO
Pembro: CPS ≥10
Nivo: TPS ≥1
Tisle: TAP ≥5
🇺🇸NCCN
Pembro, Nivo, Tisle: CPS ≥1
🇯🇵Japanese GL
Regardless of PD-L1 status
Nivo: consider TPS
Tisle: consider TAP
Pembro: no specific CPS requirement
@OncoAlert

[Rami Manochakian MD, FASCO @RManochakian]

🚨🔥@OncoAlert Hot Off The Press.

Just published @JTOonline, results of:

⭐️ #COCOON Trial

🔷The Very important #SupportiveCare randomized trial of:

Enhanced Vs Standard #Prophylactic #Dermatologic Management during Tx with #Amivantamab/#Lazertinib in patients with #EGFR+ advanced #NSCLC:

✅Significant #Reduction ⬇️ in #Dermatologic #AdverseEvents.

#COCOON #Enhanced Prophylaxis (details in 2nd picture) is now A #MUST & Standard of Care with #MARIPOSA Regimen.

👇🏻
https://t.co/HTx8Zb2QzG

[Normand Blais, MD @NormandBlais]

La guerre de désinformation est lancée par le ministre de la santé. Toutes les fautes de gestion du système seront mises sur le dos des médecins. Fake news: le DSN a été mal planifié dès le départ. Le Dossier santé numérique a du plomb dans l’aile https://t.co/3JunhVZQ4v

[Ramy @samaharamy]

@TheTravelAssist @AirCanada This is what the law says:

[Oncology Brothers @OncBrothers]

Zongertinib (oral TKI) now @US_FDA approved based off #BeamionLung1 in previously treated metastatic NSCLC w/ HER2+:

- 71% ORR w/ 14.1mos mDoR
- mPFS 12.4%
- ≥Gr 3 AEs in less than 20%. Common AEs includied diarrhea and rash

#OncTwitter #MedTwitter

[Jonathan Spicer MD PhD @DoctorJSpicer]

It seems we are in a bit of a data quagmire. I often get asked how to choose between neoadjuvant versus perioperative immunotherapy and right now there aren’t many great answers, but for what it’s worth, here’s my general perspective… #ASCO25

[Jonathan Spicer MD PhD @DoctorJSpicer]

Why is CM816 so important? After @FordePatrick beautiful presentation of these revolutionary data, let’s dig into why this unique trial should shake up our vision for oncology research…

[Sara-Maude Desforges @saramdesforges]

Proudly representing Canadian oncology at #ASCO25. The future looks bright!

[Ramy @samaharamy]

It’s unfortunate how underutilized and understudied physical activity remains in cancer management.

https://t.co/aD3C9zebrr

[Normand Blais, MD @NormandBlais]

Un poste de fellow clinique est disponible pour le programme d’oncologie thoracique médicale du @chumontreal. Les applications sont ouvertes . Avis aux intéressés!

[Ramy @samaharamy]

Keep up or get left behind
#ASCO2025

[FMSQ @FMSQ]

Non, M. Dubé, les médecins spécialistes ne quittent pas le travail à 16h le vendredi.

Nous n'avons qu'un seul objectif: soigner nos patients, et ce, peu importe l'heure ou le jour de la semaine.

Ce n'est pas d'un projet de loi que les patients ont besoin, mais d'un système bien financé avec assez de personnel soignant.
#ObjectifSoigner #polqc #santeqc
@cdube_sante

[E @utd_Eman]

Only Manchester United can make you feel like this
https://t.co/kArhZm3Rxd

[Ramy @samaharamy]

@NajiBouZeidMD @MayoSurgery @TheNRMP @MayoSurgEd Congrats naji!

[Normand Blais, MD @NormandBlais]

⚠️Proud to finally have this in published format @DrRolaS @Raafatalameddin : Clinical Utility of Liquid Biopsy for the Early Diagnosis of EGFR-Mutant Advanced Lung Cancer Patients in a Real-Life Setting (CLEAR Study) https://t.co/Q0RWDQrNT7 #mdpicurroncol

[Ramy @samaharamy]

Thrilled to share this milestone with my incredible mentor, @NormandBlais . Here’s to making #LiquidBiopsy widely accessible in Quebec—empowering patients with cutting-edge tools to overcome cancer. #Oncology #CancerResearch

https://t.co/W74pxwvwTl

[Meidas_Charise Lee @charise_lee]

Perfection 🇨🇦

[Jordi Remon @JordiRemon]

It is difficult to break the bar reached wit CT+IO in adv NSCLC all PDL1
SKYSCRAPER adding antiTIGIT to CT+IO not ⬆️PFS/OS vs CT+IO, and more toxic. Even longer mOS with CT+IO alone
New ⛔️ trial with anti-TIGIT
Should we continue with anti-TIGIT in ling? Biomarkers? #ESMOImmuno24

[Ramy @samaharamy]

@FordePatrick @NormandBlais @BertrandRouty